SCHEMBL5879261

SCHEMBL5879261

O=c1[nH]c(=O)c2c1c1[nH]c3cc(Br)ccc3c1c1c(=O)[nH]c(=O)c21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 5/20 0.59
CDK4 P11802 6/20 0.52
CCND1 P24385 6/20 0.52
CCNE2 O96020 4/20 0.52
CCNE1 P24864 4/20 0.52
CDK2 P24941 4/20 0.52
CAMK2A Q9UQM7 3/20 0.52
CAMK2B Q13554 2/20 0.52
CAMK2G Q13555 2/20 0.52
CAMK2D Q13557 2/20 0.52
CCNB2 O95067 2/20 0.52
CDK1 P06493 2/20 0.52
CCNB1 P14635 2/20 0.52
CCNB3 Q8WWL7 2/20 0.52
CDK9 P50750 2/20 0.52
CDK5 Q00535 2/20 0.52
CCNT1 O60563 1/20 0.52
EIF2AK2 P19525 1/20 0.52
CCNA2 P20248 1/20 0.52
CDK5R1 Q15078 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5879297 0.86 CHEK1 (0.59) CHEK1CDK4CCND1CCNE2CCNE1
SCHEMBL22066486 0.83 CDK4 (0.54) CDK4CCND1CCNE2CCNE1CDK2
SCHEMBL6201746 0.79 CHEK1 (0.59) CHEK1CDK4CCND1CCNE2CCNE1
SCHEMBL5879318 0.79 CHEK1 (0.59) CHEK1CDK4CCND1CCNE2CCNE1
SCHEMBL5879256 0.79 CHEK1 (0.63) CHEK1CDK4CCND1CCNE2CCNE1
SCHEMBL26543398 0.76 CDK4 (0.56) CHEK1CDK4CCND1CCNE2CCNE1
SCHEMBL5879202 0.76 CDK4 (0.62) CHEK1CDK4CCND1CCNE2CCNE1
SCHEMBL17877000 0.75 PIM3 (0.54) CDK4CCND1CCNE2CCNE1CDK2
SCHEMBL22566990 0.75 CDK4 (0.86) CHEK1CDK4CCND1CCNE2CCNE1
Bis-Imide A SCHEMBL31061368 0.74 CHEK1 (1.00) CHEK1CDK4CCND1CCNE2CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151108-B2 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATORIES SERVIER (FR) 2006-12-19 US disclosed
EP-1411057-B1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-04-27 EP disclosed
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATOIRES SERVIER (FR) 2004-04-22 US disclosed
EP-1411057-A1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2004-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents XDH, TOP2A, TOP1 CHEK1 943/4885CDK4 1989/4885CCND1 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.